Supporting evidence
Sitagliptin × HbA1c
- Authoritative support
- 3
- Available studies
- 3
- Unavailable support
- 0
Available supporting studies
Study 1 · Included
Once-weekly semaglutide improves glycemic control in Korean adults with T2D
Rct
- Comparison
- Participants received OW s.c. semaglutide 0.5 mg. · Participants received OW s.c. semaglutide 1.0 mg. · Participants received OD oral sitagliptin 100 mg.
- Duration / follow-up
- 30 weeks
Relevant effects
Percent change
1.6
Percent change
80
Percent change
60
Percent change
1.8
Percent change
87.5
Percent change
67.5
Percent change
0.9
Percent change
54.3
Percent change
25.7
Study 2 · Included
Oral semaglutide improves glycemic control in type 2 diabetes
Rct
- Comparison
- Participants received once daily oral semaglutide 3 mg. · Participants received once daily oral semaglutide 7 mg. · Participants received once daily oral semaglutide 14 mg. · Participants received once daily oral sitagliptin 100 mg.
- Duration / follow-up
- 26 weeks
Relevant effects
Mean difference
2 · 0.001
Mean difference
8 · 0.001
Mean difference
11 · 0.001
Mean difference
11 · 0.001
Study 3 · Limited
Sitagliptin shows no additional benefit on carotid thickness in diabetes
- Comparison
- Participants receiving sitagliptin in addition to conventional therapy. · Participants receiving only conventional therapy (diet, exercise, and/or antidiabetic agents).
- Duration / follow-up
- 104 weeks
Relevant effect
Mean difference
0.159 · 0.008